Targeted therapy for thyroid cancer: Striking the survival signaling

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 4, 2011, Pages 936-938

  Vitale, Mario ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MK 2206; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN RET; RAF PROTEIN; RAS PROTEIN; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER SURVIVAL; DRUG TARGETING; EDITORIAL; GENE OVEREXPRESSION; GENE REARRANGEMENT; HUMAN; KIDNEY CARCINOMA; MELANOMA; ONCOGENE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PTEN GENE; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID PAPILLARY CARCINOMA; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, PAPILLARY, FOLLICULAR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; RAF KINASES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 79953889866     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2011-0347     Document Type: Editorial

References (21)

1. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R 2004 B-RAF is a therapeutic target in melanoma. Oncogene 23:6292-6298 (Pubitemid 39215299)
2. Montagut C, Sharma SV, Shioda T, McDermott U, UlmanM,Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J 2008 Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68:4853-4861
3. Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, Elder DE, Flaherty KT, Herlyn M, Nathanson KL 2008 Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 7:2876-2883
4. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, Garraway LA 2009 MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 106:20411-20416
5. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A, Vegetti C, Nonaka D, Mortarini R, Parmiani G, Fais S, Anichini A 2006 Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25:3357-3364 (Pubitemid 43877040)
6. Lin J, Goto Y, Murata H, Sakaizawa K, Uchiyama A, Saida T, Takata M 2011 Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer 104:464-468
7. Kimura ET, NikiforovaMN,Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RASBRAFsignaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457 (Pubitemid 36373628)
8. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A,Máximo V, Botelho T, Seruca R, Sobrinho-Simõ esM2003 BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22:4578-4580 (Pubitemid 36920701)
9. Zhu Z, Ciampi R, Nikiforova MN, Gandhi M, Nikiforov YE 2006 Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: Effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 91:3603-3610 (Pubitemid 44402144)
10. Wang YL, Wang JC, Wu Y, Zhang L, Huang CP, Shen Q, Zhu YX, Li DS, Ji QH 2008 Incidentally simultaneous occurrence of RET/ PTC, H4-PTEN and BRAF mutation in papillary thyroid carcinoma. Cancer Lett 263:44-52
11. Henderson YC, Shellenberger TD, Williams MD, El-Naggar AK, Fredrick MJ, Cieply KM, Clayman GL 2009 High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res 15:485-491
12. Folkman J 1971 Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186
13. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garciadel- Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA 2009 Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-3590
14. Koutras AK, Fountzilas G, Makatsoris T, Peroukides S, Kalofonos HP 2010 Bevacizumab in the treatment of breast cancer. Cancer Treat Rev 36:75-82
15. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J 1994 Phosphatidylinositol- 3-OH kinase as a direct target of Ras. Nature 370:527-532 (Pubitemid 24264918)
16. Jung HS, Kim DW, Jo YS, Chung HK, Song JH, Park JS, Park KC, Park SH, Hwang JH, Jo KW, ShongM2005 Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases. Mol Endocrinol 19:2748-2759 (Pubitemid 41577247)
17. Xing M 2010 Genetic alterations in the phosphatidylinositol-3 kinase/ Akt pathway in thyroid cancer. Thyroid 20:697-706
18. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, XingM2007 Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/ Akt pathway in thyroid cancer. Clin Cancer Res 13:1161-1170 (Pubitemid 46424056)
19. Hou P, Ji M, Xing M 2008 Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 113:2440-2447
20. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H 2010 MK- 2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9:1956-1967
21. Liu R, Liu D, Trink E, Bojdani E, Ning G, Xing M 2011 The Aktspecific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. J Clin Endocrinol Metab 96:E577-E585